UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Targeting of activated fibroblasts for imaging and therapy

EJNMMI radiopharmacy and chemistry, 2019-07, Vol.4 (1), p.16-16, Article 16

2019

Link zum Volltext

Verfügbarkeit prüfen

[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma

European journal of nuclear medicine and molecular imaging, 2021-08, Vol.48 (9), p.3011-3013

2021

Link zum Volltext

Verfügbarkeit prüfen

Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease

European journal of nuclear medicine and molecular imaging, 2020-07, Vol.47 (8), p.2040-2041

2020

Link zum Volltext

Verfügbarkeit prüfen

Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model

European journal of nuclear medicine and molecular imaging, 2022-02, Vol.49 (3), p.871-880

2022

Link zum Volltext

Verfügbarkeit prüfen

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

European journal of nuclear medicine and molecular imaging, 2021-01, Vol.48 (1), p.113-122

2021

Link zum Volltext

Verfügbarkeit prüfen

Radioligands Targeting Fibroblast Activation Protein (FAP)

Cancers, 2021-11, Vol.13 (22), p.5744

2021

Link zum Volltext

Verfügbarkeit prüfen

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging

Annals of nuclear medicine, 2022-03, Vol.36 (3), p.293-301

2022

Link zum Volltext

Verfügbarkeit prüfen

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

Cancers, 2021-09, Vol.13 (19), p.4946

2021

Link zum Volltext

Verfügbarkeit prüfen

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT

European journal of nuclear medicine and molecular imaging, 2021-06, Vol.48 (6), p.2059-2061

2021

Link zum Volltext

Verfügbarkeit prüfen

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

The Lancet (British edition), 2012-05, Vol.379 (9828), p.1791-1799

2012

Link zum Volltext

Verfügbarkeit prüfen

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

European journal of nuclear medicine and molecular imaging, 2021-11, Vol.48 (12), p.4067-4076

2021

Link zum Volltext

Verfügbarkeit prüfen

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer

Seminars in nuclear medicine, 2016-09, Vol.46 (5), p.405-418

2016

Link zum Volltext

Verfügbarkeit prüfen

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

European journal of nuclear medicine and molecular imaging, 2021-12, Vol.49 (1), p.54-63

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

European journal of nuclear medicine and molecular imaging, 2021-01, Vol.48 (1), p.143-151

2021

Link zum Volltext

Verfügbarkeit prüfen

The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer

Molecular imaging and biology, 2024-02, Vol.26 (1), p.81-89

2024

Link zum Volltext

Verfügbarkeit prüfen

First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT

European journal of nuclear medicine and molecular imaging, 2021, Vol.48 (1), p.311-312

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas

Scientific reports, 2023-10, Vol.13 (1), p.17848-17848, Article 17848

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

Journal of cancer research and clinical oncology, 2021-08, Vol.147 (8), p.2471-2481

2021

Link zum Volltext

Verfügbarkeit prüfen

68Ga-FAPI-PET/CT in patients with various gynecological malignancies

European journal of nuclear medicine and molecular imaging, 2021-11, Vol.48 (12), p.4089-4100

2021

Link zum Volltext

Verfügbarkeit prüfen

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

European journal of nuclear medicine and molecular imaging, 2021-12, Vol.48 (13), p.4377-4385

2021

Link zum Volltext

Verfügbarkeit prüfen

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74

Cancers, 2022-10, Vol.14 (21), p.5301

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

Prostate cancer and prostatic diseases, 2022-03, Vol.25 (1), p.71-78

2022

Link zum Volltext

Verfügbarkeit prüfen

18F-labeled tracers targeting fibroblast activation protein

EJNMMI radiopharmacy and chemistry, 2021-08, Vol.6 (1), p.1-13, Article 26

2021

Link zum Volltext

Verfügbarkeit prüfen

Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases

Endocrine-related cancer, 2011-10, Vol.18 (5), p.595-602

2011

Link zum Volltext

Verfügbarkeit prüfen

Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma

Cancers, 2021-03, Vol.13 (7), p.1508

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 282

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(269)
Mit Volltextzugriff
(271)

Publikationsform

Sprache

Englisch
(274)
Deutsch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(106)
Male
(80)
Science & Technology
(77)
Life Sciences & Biomedicine
(75)
Prostate Cancer
(75)
Oncology
(57)
Patients
(56)
Radiology, Nuclear Medicine & Medical Imaging
(56)
Tumors
(53)
Nuclear Medicine
(52)
Metastases
(48)
Middle Aged
(47)
Positron Emission
(47)
Tomography
(46)
Computed Tomography
(45)
Imaging
(45)
Radiology
(45)
Medicine
(44)
Medicine & Public Health
(44)
Aged
(40)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Targeting of activated fibroblasts for imaging and therapy

[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma

Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease

Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

Radioligands Targeting Fibroblast Activation Protein (FAP)

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer

First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT

Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas

Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities

68Ga-FAPI-PET/CT in patients with various gynecological malignancies

Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74

Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

18F-labeled tracers targeting fibroblast activation protein

Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases

Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma

Suchergebnisse filtern